The SAHMRI Metabolomics and Lipidomics Core Facility is focused on providing a world-class small molecule analysis service.

The facility offers a wide range of services ranging from global plasma lipidomics, metabolomics, fluxomics to highly targeted quantification of small molecules, both endogenous such as neurotransmitters and xenobiotic like small molecule drugs.

Although only established as a core facility in 2019, the group has a long history going back over two decades. It grew out of the mass spectrometry group of the Lysosomal Diseases Research Unit in Adelaide, then primarily working on mass spectrometry-based analysis methods to study the primary and secondary substrates of lysosomal storage disorders (lipids and glycosaminoglycans).

The facility operates on a fee-for-service basis. Some equipment can be booked subject to training and permission from the Facility Manager.

Services and Capabilities

• Metabolomics and Fluxomics using an Agilent 6546 QTof coupled to a 1290 Infinity II UHPLC system and Bruker timsTOF Flex
• Lipidomics using a Waters Xevo G2-XS QTof coupled to a Waters ACQUITY UPLC I-Class system
• Targeted LC-MS/MS using a SCIEX 4000 QTrap or SCIEX 5500 QqQ coupled to a Waters ACQUITY UPLC system
• Development of validated quantitative methods following US FDA Guidelines for Bioanalysis
• Automated sample preparation for large sample sets using Agilent Bravo Metabolomics Sample Prep Platform
• Data analysis
  - Bruker MetaboScape
  - Agilent VistaFlux
  - Agilent MassHunter
  - Waters Progenesis QI
  - Skyline
  - MetaboAnalyst